Clinical trials: Uterine Diseases
Cervical Cancer, Vulvar Cancer
Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001)
The purpose of this study was to evaluate the safety, efficacy, and immunogenicity of V503 in comparison to GARDASIL. The primary hypotheses tested in the study were 1) V503 administered to 16- to 26-year-old adolescents and…
- Conditions
- Cervical Cancer, Vulvar Cancer, Vaginal Cancer, Genital Warts
- Trial name
- NCT00543543
- Testing
- Comparator: GARDASIL, Experimental: V503
- Volunteers
- 14,840 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Cervical Cancer
Comparison of Different Subsequent Treatments After Radical Surgery
Cervical cancer is still the most common gynecologic cancer. There was no obvious increase of the survival over years. The risk of recurrence after radical surgery has increased with positive lymph nodes, positive surgical…
- Trial name
- STARS (NCT00806117)
- Testing
- Radiotherapy (RT), Concurrent chemoirradiation (CCRT), Sequence chemotherapy and radiotherapy (SCRT)
- Where
- China
- Volunteers
- 1,080 people
- Sponsor
- Sun Yat-sen University
Vaginitis Bacterial, Cervicitis
Empiric Therapy of Mucopurulent Cervicitis (MPC)
Mucopurulent cervicitis (MPC) is a syndrome with associated symptoms including mucopurulent discharge (mucus and pus) from the cervix and other signs of inflammation such as easily induced cervical bleeding.
- Trial name
- NCT01072136
- Testing
- Azithromycin, Cefixime
- Where
- 4 sites in United States
- Volunteers
- 87 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Advanced Solid Tumors, Colorectal Cancer (CRC)
A Study to Investigate the Safety and Efficacy of KQB368 as Monotherapy in Participants With Advanced Solid Malignancies
The goal of this study is to learn if KQB368 works to treat advanced solid malignancies in adults. The study will also learn about the safety of KQB368.
- Conditions
- Advanced Solid Tumors, Colorectal Cancer (CRC), Non-Small Cell Lung Cancer, Uterine Cancer
- Trial name
- NCT07542704
- Testing
- KQB368
- Volunteers
- 48 people
- Sponsor
- Kumquat Biosciences Inc.
Postpartum Hemorrhage
Intramuscular Versus Intravenous Prophylactic Oxytocin for Hemorrhage After Vaginal Delivery
Intramuscular versus intravenous prophylactic oxytocin for the third stage of labour following vaginal delivery: A randomised controlled trial
- Trial name
- oxytocin (NCT02080104)
- Testing
- intarvenous and intramusculer 10 IU oxytocin
- Where
- Turkey (Türkiye)
- Volunteers
- 2 people
- Sponsor
- Hediye Dagdeviren
Endometrial Cancer
Raloxifene in Treating Patients With Persistent or Recurrent Endometrial Cancer
RATIONALE: Estrogen can stimulate the growth of endometrial cancer cells. Hormone therapy using raloxifene may fight endometrial cancer by reducing the production of estrogen.
- Trial name
- NCT00004915
- Testing
- raloxifene
- Where
- United States
- Sponsor
- Northwestern University
Cervix Cancer
Image-guided Adaptive Radiotherapy for Cervix Cancer: Patient Image Acquisition
Within this study patient data are collected from different imaging and motion monitoring devices that will be used to develop and test strategies for image-guided adaptive radiotherapy in cervix cancer patients.
- Trial name
- NCT00571415
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Virginia Commonwealth University
Recurrent or Persistent Endometrial Carcinoma
Virexxa (Sodium Cridanimod) w/Progestin Therapy in Pts w/Progesterone Receptor Neg Recurrent/Persistent Endometrial CA
This is an open label, multi-center, single arm phase II study. The study will investigate the efficacy of sodium cridanimod in conjunction with progestin therapy in a population of patients with recurrent or persistent…
- Trial name
- NCT02064725
- Testing
- Sodium cridanimod
- Where
- 21 sites in United States, Belarus and 3 more
- Volunteers
- 8 people
- Sponsor
- Kevelt AS
Adult Alveolar Soft Part Sarcoma, Adult Angiosarcoma
Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma
This randomized phase I/II clinical trial is studying the side effects and best dose of gamma-secretase/notch signalling pathway inhibitor RO4929097 when given together with vismodegib and to see how well they work in treating…
- Conditions
- Adult Alveolar Soft Part Sarcoma, Adult Angiosarcoma, Adult Desmoplastic Small Round Cell Tumor, Adult Epithelioid Hemangioendothelioma
- Trial name
- NCT01154452
- Testing
- Gamma-Secretase Inhibitor RO4929097, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- National Cancer Institute (NCI)
Endometrial Cancer
From Fetal-maternal Interface Immune Tolerance to Endometrial Cancer Immune Escape: Potential Targets for Immunotherapy
Non-interventional retro-prospective study on Endometrial tissue samples taken from surgically treated patients.
- Trial name
- NCT06273878
- Where
- 2 sites in Italy
- Volunteers
- 80 people
- Sponsor
- Regina Elena Cancer Institute
Precancerous Lesions, Conization
A Cohort Study for the Following up of Conization
This study is to investigate the oncologic and obstetric outcomes in patients with conization for uterine cervical lesions from January 1, 2000 to January 1, 2019 in Peking Union Medical College Hospital.
- Conditions
- Precancerous Lesions, Conization, High Grade Intraepithelial Neoplasia, Uterine Cervical Cancer
- Trial name
- NCT03961178
- Testing
- High-risk HPV, TCT
- Where
- China
- Volunteers
- 10,000 people
- Sponsor
- Lei Li
Cervix Neoplasms, Uterine Neoplasms
Intensity Modulated Radiation Therapy - Gyne Cancer (GY03.2)
Standard treatment for gynecological cancer is radiation therapy in two phases; whole pelvic radiation and then an internal radiation boost, also called a brachytherapy boost, to treat any remaining tumour.
- Conditions
- Cervix Neoplasms, Uterine Neoplasms, Vaginal Neoplasms
- Trial name
- NCT00188578
- Testing
- Intensity Modulated Radiation Therapy Boost
- Where
- Canada
- Volunteers
- 12 people
- Sponsor
- University Health Network, Toronto
Postpartum Hemorrhage (PPH), Placental Dysfunction
Risk Factors for Postpartum Hemorrhage in Patients With Histologically Verified Placenta Accreta
This retrospective, monocentric study aims to examine risk factors for postpartum hemorrhage in women with histologically verified placenta accreta.
- Trial name
- NCT05542043
- Testing
- Data collection
- Where
- Switzerland
- Volunteers
- 2,348 people
- Sponsor
- University Hospital, Basel, Switzerland
Uterine Leiomyoma, Uterine Fibroids
MR Guided Focused Ultrasound Treatment of Uterine Fibroids With Enhanced Sonication
This is a phase 3 study to determine the safety of the new features to the FDA approved ExAblate device using a new method to ablate fibroids deemed Enhanced Sonication.
- Trial name
- NCT00365989
- Testing
- ExAblate Enhanced Sonication
- Where
- 5 sites in United States, Canada
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- InSightec
Uterine Diseases
Do müllerian Anomalies Affect Embryo Implantation?
Müllerian anomalies (MA) are associated with infertility and affect approximately 6.3% of the infertile population. The estimation of the frequency of MAs is not without controversy because it depends on the diagnostic method…
- Trial name
- AM (NCT04571671)
- Testing
- Collect retrospectively data
- Volunteers
- 5,000 people
- Sponsor
- IVI Vigo
Sarcoma
Exatecan Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of exatecan mesylate in treating patients who have…
- Trial name
- NCT00041236
- Testing
- exatecan mesylate
- Where
- 10 sites in Belgium, Denmark and 2 more
- Volunteers
- 39 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Solid Tumors With PTCH1 Loss-of-function Mutations
A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
This study employs a 2-stage design that aims to evaluate the efficacy and safety of ENV- 101, a potent Hedgehog (Hh) pathway inhibitor, in patients with refractory advanced solid tumors characterized by loss of function (LOF)…
- Trial name
- NCT05199584
- Testing
- ENV-101 (taladegib)
- Where
- 16 sites in United States
- Volunteers
- 20 people
- Sponsor
- Endeavor Biomedicines, Inc.
Cancer
Safety, Pharmacokinetics (PK) of AKT and MEK Combination
This study is a Phase 1 dose-escalation open-label study to determine the recommended Phase II dose (RP2D) and regimen for the combination of the orally administered MEK inhibitor GSK1120212 and the orally administered AKT kinase…
- Trial name
- NCT01138085
- Testing
- GSK1120212, GSK2141795
- Where
- 10 sites in United States
- Volunteers
- 240 people
- Sponsor
- GlaxoSmithKline
Cervical Cancer
Study of Cisplatin in Cervical Cancer Stage IVB
This is a single arm, open-label study in women from China who have Advanced (stage IVB) Recurrent or Persistent cervical cancer to ⑴assess the response rate (i.e., CR + PR) of Cisplatin combined with Topotecan in treatment of…
- Trial name
- NCT00826891
- Testing
- Cisplatin Combined With Topotecan
- Volunteers
- 40 people
- Sponsor
- Chinese Anti-Cancer Association
Cervical Cancer Stage IB2, Cervical Cancer Stage IIa
Pilot Study for the Generation of Cervical Cancer Organoids From Patients Undergoing Diagnostic Biopsy
A meta-analysis showed that neoadjuvant chemotherapy followed by radical hysterectomy reduces the risk of mortality by 35% compared to radiotherapy alone, with a 14% increase in five-year survival.
- Conditions
- Cervical Cancer Stage IB2, Cervical Cancer Stage IIa, Cervical Cancer Stage IB, Cervical Cancer Stage IIIA
- Trial name
- Cervical organ (NCT07248878)
- Where
- Italy
- Volunteers
- 24 people
- Sponsor
- Regina Elena Cancer Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.